使用地拉曼德治疗的耐多药结核病患者的长期死亡率评估
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.
作者信息
Wells Charles D, Gupta Rajesh, Hittel Norbert, Geiter Lawrence J
机构信息
Otsuka Pharmaceutical Development and Commercialization, Rockville, MD, USA
Otsuka Pharmaceutical Development and Commercialization, Rockville, MD, USA.
出版信息
Eur Respir J. 2015 May;45(5):1498-501. doi: 10.1183/09031936.00176314. Epub 2015 Feb 19.
Abstract
摘要
这看起来是一个网址链接，无法直接翻译为中文，保留原文“http://ow.ly/HOv1d”
相似文献
1
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.
Eur Respir J. 2015 May;45(5):1498-501. doi: 10.1183/09031936.00176314. Epub 2015 Feb 19.
2
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.
3
Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Lancet Respir Med. 2017 Oct;5(10):772-774. doi: 10.1016/S2213-2600(17)30309-0. Epub 2017 Sep 5.
4
Delamanid for multidrug-resistant pulmonary tuberculosis.
N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433.
5
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
Eur Respir J. 2017 Nov 9;50(5). doi: 10.1183/13993003.01105-2017. Print 2017 Nov.
6
Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
Drugs Today (Barc). 2015 Feb;51(2):117-23. doi: 10.1358/dot.2015.51.2.2245645.
7
Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis.
Prescrire Int. 2017 Apr;26(181):89-92.
8
Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
Drugs. 2015 Jan;75(1):91-100. doi: 10.1007/s40265-014-0331-4.
9
Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.
Clin Infect Dis. 2020 Jul 11;71(2):415-418. doi: 10.1093/cid/ciz1084.
10
Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
Eur Respir J. 2018 Jun 14;51(6). doi: 10.1183/13993003.00159-2018. Print 2018 Jun.
引用本文的文献
1
Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review.
GMS Hyg Infect Control. 2025 Jun 26;20:Doc33. doi: 10.3205/dgkh000562. eCollection 2025.
2
Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis.
Int J Infect Dis. 2022 Nov;124 Suppl 1(Suppl 1):S90-S103. doi: 10.1016/j.ijid.2022.02.043. Epub 2022 Mar 2.
3
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.
Microorganisms. 2021 May 17;9(5):1074. doi: 10.3390/microorganisms9051074.
4
Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance.
Futur J Pharm Sci. 2021;7(1):56. doi: 10.1186/s43094-021-00196-5. Epub 2021 Mar 3.
5
Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01207-20.
6
Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01202-20.
7
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
Am J Respir Crit Care Med. 2021 Jan 1;203(1):111-119. doi: 10.1164/rccm.202001-0135OC.
8
Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.
MMWR Morb Mortal Wkly Rep. 2018 Sep 7;67(35):996-997. doi: 10.15585/mmwr.mm6735a6.
9
Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center Study.
Am J Trop Med Hyg. 2018 Jun;98(6):1629-1636. doi: 10.4269/ajtmh.17-0936. Epub 2018 Mar 29.
10
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.
Eur Respir J. 2017 Jul 27;50(1). doi: 10.1183/13993003.00311-2017. Print 2017 Jul.
本文引用的文献
1
Delamanid: first global approval.
Drugs. 2014 Jun;74(9):1041-5. doi: 10.1007/s40265-014-0241-5.
2
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.
Eur Respir J. 2013 Jul;42(1):156-68. doi: 10.1183/09031936.00134712. Epub 2012 Oct 25.
3
Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.
Eur Respir J. 2013 Jul;42(1):169-179. doi: 10.1183/09031936.00136312. Epub 2012 Oct 11.
4
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.
5
Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.
Tuberculosis (Edinb). 2012 Sep;92(5):397-403. doi: 10.1016/j.tube.2012.06.003. Epub 2012 Jul 10.
6
Delamanid for multidrug-resistant pulmonary tuberculosis.
N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433.
7
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.
J Infect Dis. 2012 May 15;205 Suppl 2:S241-9. doi: 10.1093/infdis/jis034. Epub 2012 Mar 22.
8
Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects.
Int J Tuberc Lung Dis. 2011 Oct;15(10):1315-22. doi: 10.5588/ijtld.10.0221.
9
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.
Eur Respir J. 2011 Sep;38(3):516-28. doi: 10.1183/09031936.00073611. Epub 2011 Aug 4.
10
Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004.
Eur Respir J. 2010 Sep;36(3):584-93. doi: 10.1183/09031936.00003710. Epub 2010 Feb 25.
Zotero 插件